Cameco Slides with the Uranium Pack as Valuation Premium Narrows

CCO heads into the week of September 16 having shed nearly 10% in five trading sessions, part of a broad uranium-sector pullback that is compressing a rich valuation and sharpening the question of whether the premium is still earned.

The sector selloff is not Cameco-specific. Across the uranium peer group, every name tracked by ORTEX posted heavy losses on the week. NXE dropped roughly 11%, DML fell almost 14%, UEC lost more than 14%, and LEU was the worst performer at nearly 24% down. EFR shed 18%. Cameco's 9.8% decline actually makes it one of the more resilient names in the group. That relative outperformance is consistent with the stock's status as the highest-quality large-cap in the uranium complex — but it also starts from a more stretched multiple, which means the valuation conversation is less forgiving.

The lending market offers no sign that short sellers are driving the move. Short interest runs at roughly 0.98% of the free float — barely a rounding error in a $50-billion enterprise-value stock. That figure has crept up about 27% over the past month in absolute share terms, but starting from such a low base the move is more noise than signal. Borrow costs have actually fallen sharply: cost to borrow came in at 0.53%, nearly 41% lower than a week ago, and availability is extraordinarily loose at over 6,800% of short interest, meaning there are vastly more shares available to lend than are currently borrowed. None of this suggests short sellers are loading up. The selling pressure is coming from long holders, not new shorts.

The valuation compression is the more actionable story. Cameco's trailing P/E has contracted to 55.6x from around 62x thirty days ago — still elevated, but visibly moving. The EV/EBITDA multiple declined nearly 1.8 turns over the same period to 24.4x. The price-to-book dropped from roughly 7.1x to 6.5x. None of those numbers yet look cheap for a business in a capital-intensive, commodity-exposed sector. The EV/EBIT factor score ranks in the first percentile of the ORTEX universe, confirming how extended the valuation remains on earnings-based measures. EPS momentum scores provide some offset — the 30-day reading ranks in the 76th percentile and the 12-month forward EPS growth rank is at the 87th — so the Street still sees earnings power building. Analyst data in the system is significantly stale and should not be relied on for current targets.

Institutional ownership broadly reflects a conventional long-only holder base, with Vanguard, Mirae Asset, and Capital Research among the top reported holders. BlackRock filed a Schedule 13G in late July disclosing a 5.02% stake, up from 4.3% previously — a passive accumulation at what were then higher prices around $140. FMR (Fidelity) moved the other way, with its last 13G/A showing its stake fell from 5.2% to 3.4%. Neither filing signals activist intent; both are standard disclosure events around the 5% threshold, and positions may have shifted further since the filing dates. Insider activity since June consists of small open-market sales totalling around $64,000 net over 90 days — immaterial relative to the stock's size, and all graded at low significance.

The next scheduled event is Q3 earnings on October 30. The last print on July 31 produced a 6% one-day gain and nearly 10% over the following week — a strong positive reaction. The May print moved the stock nearly 5% lower. The earnings setup will therefore be worth revisiting once the uranium spot price and sector sentiment stabilise: the key question heading into October is whether the forward earnings momentum that currently justifies the premium multiple can hold through the next reporting cycle, or whether the sector re-rating accelerates the valuation compression already underway.